Idogen updates in connection with the Swedish Medical Products Agency's approval of phase 1/2a study
Anders Karlsson, CEO of Idogen AB, visited BioStock's studio in connection with the company receiving the Swedish Medicines Agency's approval of its clinical phase 1/2a study for IDO 8, a completely new type of cell therapy for patients with severe hemophilia A who have developed antibodies to its vital treatment with coagulation factor VIII. The purpose of IDO 8 is to create tolerance for and enable continued treatment with factor VIII. The clinical study has been designed in close dialogue with leading specialists in coagulation disorders and regulatory authorities in the Nordic